<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7151825\results\search\disease\results.xml">
  <result pre="all travelers including those who are immunosuppressed The interaction between" exact="tuberculosis" post="and immunosuppression will be discussed in a separate chapter."/>
  <result pre="differently based on their training and experience. For example, national" exact="malaria" post="guidelines differ in their advice for certain countries, and"/>
  <result pre="do no harm�?. An example of this might be avoiding" exact="yellow fever" post="vaccination in a significantly immunosuppressed traveler who chooses to"/>
  <result pre="traveler can be considered: •Vaccine preventable infections •Vector-borne diseases, e.g.," exact="malaria" post="•Other nonvaccine preventable infections, e.g., traveler's diarrhea (TD) •Noninfectious"/>
  <result pre="•Vector-borne diseases, e.g., malaria •Other nonvaccine preventable infections, e.g., traveler's" exact="diarrhea" post="(TD) •Noninfectious considerations, e.g., travel insurance and road safety"/>
  <result pre="may lead to harm. Individuals often develop partial immunity to" exact="malaria" post="if they grow up in a highly endemic area,"/>
  <result pre="in a highly endemic area, leading to the perception of" exact="malaria" post="as a minor illness in adults. This partial immunity"/>
  <result pre="VFR travelers were more likely to receive a diagnosis of" exact="malaria" post="or viral hepatitis compared to non-VFR travelers. They were"/>
  <result pre="were more likely to receive a diagnosis of malaria or" exact="viral hepatitis" post="compared to non-VFR travelers. They were also less likely"/>
  <result pre="more likely to receive a diagnosis of malaria or viral" exact="hepatitis" post="compared to non-VFR travelers. They were also less likely"/>
  <result pre="seek pretravel advice [5]. 3 Types of immunosuppression used in" exact="autoimmune disease" post="and their mechanisms of action 3.1 Defining immunosuppression Immunosuppression"/>
  <result pre="given for another reason, for example anti-inflammatory treatments given for" exact="autoimmune disease." post="The exact immune defect and resulting risk of infection"/>
  <result pre="their immune defect. 3.2 Biological therapies Autoimmune diseases such as" exact="rheumatoid arthritis" post="are characterized by persistent, abnormal inflammation. Inflammatory cytokines or"/>
  <result pre="immune defect. 3.2 Biological therapies Autoimmune diseases such as rheumatoid" exact="arthritis" post="are characterized by persistent, abnormal inflammation. Inflammatory cytokines or"/>
  <result pre="that specifically target these cytokines has revolutionized the treatment of" exact="autoimmune disease." post="This specificity is in contrast to other traditional, &quot;nonspecific�?"/>
  <result pre="been associated with an increased susceptibility to several infections including" exact="tuberculosis" post="and nontuberculous mycobacterial infection. Invasive fungal infections such as"/>
  <result pre="tuberculosis and nontuberculous mycobacterial infection. Invasive fungal infections such as" exact="histoplasmosis" post="and coccidioidomycosis are also associated with TNF-alpha blockers, as"/>
  <result pre="nontuberculous mycobacterial infection. Invasive fungal infections such as histoplasmosis and" exact="coccidioidomycosis" post="are also associated with TNF-alpha blockers, as are certain"/>
  <result pre="with TNF-alpha blockers, as are certain bacterial infections such as" exact="listeriosis" post="and Legionella pneumonia. TNF-alpha blockers have also been associated"/>
  <result pre="TNF-alpha blockers have also been associated with severe reactivation of" exact="hepatitis" post="B in patients with chronic infection [6]. 3.4 TNF-alpha"/>
  <result pre="cell depletion. Its use has been associated with reactivation of" exact="hepatitis" post="B, severe Pneumocystis jirovecii (carinii) infection, and progressive multifocal"/>
  <result pre="reactivation of hepatitis B, severe Pneumocystis jirovecii (carinii) infection, and" exact="progressive multifocal leukoencephalopathy" post="(PML) [6]. 3.6 Nonbiological drugs 3.6.1 Glucocorticoids Glucocorticoids such"/>
  <result pre="infections. 3.6.2 Methotrexate Methotrexate is another nonbiological therapy used in" exact="autoimmune disease." post="It was first developed as a chemotherapy agent and"/>
  <result pre="and pyrimidines. It was later introduced as a treatment for" exact="rheumatoid arthritis" post="due to its anti-inflammatory effects. It is used at"/>
  <result pre="pyrimidines. It was later introduced as a treatment for rheumatoid" exact="arthritis" post="due to its anti-inflammatory effects. It is used at"/>
  <result pre="It is used at low doses for long-term therapy in" exact="rheumatoid arthritis" post="unlike in malignancy where it is used at much"/>
  <result pre="is used at low doses for long-term therapy in rheumatoid" exact="arthritis" post="unlike in malignancy where it is used at much"/>
  <result pre="an immune response to inactivated vaccines. Immunosuppression used to treat" exact="autoimmune disease" post="may be limited or significant as outlined below: 4.1"/>
  <result pre="mg/kg/week or azathioprine at doses of ≤3 mg/kg/day •Travelers with" exact="autoimmune disease" post="who are not being treated with immunosuppressive or immunomodulatory"/>
  <result pre="the routine vaccination schedule in many countries infections such as" exact="measles" post="remain common in parts of Asia and Africa. Decreased"/>
  <result pre="Specialist advice from local virology, travel medicine, clinical immunology, or" exact="infectious disease" post="services should be sought in these circumstances [12]. 5.2"/>
  <result pre="circumstances [12]. 5.2 Live vaccinations available in Europe [12] •Live" exact="influenza" post="vaccine (inactivated vaccines are also available) •Measles, Mumps, and"/>
  <result pre="outbreak. Guidance from the WHO suggests that one dose of" exact="yellow fever" post="vaccination offers lifelong protection in most cases, and a"/>
  <result pre="[17]. Although an effective live attenuated vaccine is available against" exact="yellow fever," post="it is contraindicated in significantly immunosuppressed patients due to"/>
  <result pre="disease [9]. Such travelers who have not been vaccinated against" exact="yellow fever" post="should be discouraged from traveling to endemic areas. If"/>
  <result pre="unavoidable, then they should be informed of the risk of" exact="yellow fever" post="in their destination and the importance of strict mosquito"/>
  <result pre="bite avoidance measures [18]. In general, the risk of developing" exact="yellow fever" post="is 10 times higher from travel to sub-Saharan Africa"/>
  <result pre="were estimated to be 14.3 million cases of typhoid and" exact="paratyphoid fever" post="globally in 2017 and 135.9000 deaths; a case fatality"/>
  <result pre="There is currently an outbreak of extensively drug resistant (XDR)" exact="typhoid fever" post="in Pakistan where almost two-thirds of isolates from Sindh"/>
  <result pre="Sindh Province were resistant to all the recommended antibiotics for" exact="typhoid fever" post="from November 2016 to December 2018. Six travel-associated cases"/>
  <result pre="A is a viral infection of the liver caused by" exact="hepatitis" post="A virus. It is spread via the fecal–oral route"/>
  <result pre="and jaundice may occur in 70%–80% of infected adults. Fulminant" exact="hepatitis" post="is rare and unlike hepatitis B and C there"/>
  <result pre="70%–80% of infected adults. Fulminant hepatitis is rare and unlike" exact="hepatitis" post="B and C there is no chronic carrier state."/>
  <result pre="is generally low but is increased in those with preexisting" exact="liver disease" post="and older adults [26]. Hepatitis A infection may be"/>
  <result pre="A infection may be severe in immunocompromised patients [27]. Different" exact="hepatitis" post="A vaccines are available; there is a monovalent vaccine"/>
  <result pre="a monovalent vaccine as well as polyvalent vaccines combined with" exact="hepatitis" post="B or typhoid. All the vaccines are inactivated and"/>
  <result pre="notifiable disease in many countries. 6.4 Rabies Rabies is an" exact="infectious disease" post="caused by neurotropic viruses of the genus Lyssavirus. A"/>
  <result pre="Lyssavirus. A total 99% of human cases are caused by" exact="rabies" post="virus genotype 1. Dogs are the main vector for"/>
  <result pre="effective medical treatment once the disease has taken hold. Most" exact="rabies" post="cases are reported in Africa and Asia, and there"/>
  <result pre="are common. Travelers should be educated about the risks of" exact="rabies" post="and advised to avoid contact with wild and domestic"/>
  <result pre="vaccine can be thought of as an insurance policy; although" exact="rabies" post="is rare in travelers and the vaccine is expensive,"/>
  <result pre="on the body the exposure occurred, any risk of immunosuppression," exact="allergy" post="status, and previous rabies vaccination status [28]. All possible"/>
  <result pre="exposure occurred, any risk of immunosuppression, allergy status, and previous" exact="rabies" post="vaccination status [28]. All possible rabies exposures, including contact"/>
  <result pre="allergy status, and previous rabies vaccination status [28]. All possible" exact="rabies" post="exposures, including contact with bats, should be discussed with"/>
  <result pre="longer course of postexposure vaccination. They will also require human" exact="rabies" post="immunoglobulin (HRIG) following a significant exposure. This is infiltrated"/>
  <result pre="significant exposure. This is infiltrated around the wound and neutralizes" exact="rabies" post="virus at the wound site. Due to the risk"/>
  <result pre="The commonest presentations of meningococcal disease are meningitis, septicemia, or" exact="meningitis" post="with accompanying septicemia [32]. There are multiple strains of"/>
  <result pre="[32]. Meningococcal disease is notifiable in many countries. Outline of" exact="meningitis" post="belt in Africa showing average annual attack rates [36]."/>
  <result pre="Africa showing average annual attack rates [36]. 6.6 Influenza Human" exact="influenza" post="A and B viruses cause seasonal outbreaks of influenza"/>
  <result pre="Human influenza A and B viruses cause seasonal outbreaks of" exact="influenza" post="or &quot;flu�? worldwide. Influenza A viruses can also cause"/>
  <result pre="in most cases; however, severe disease with complications such as" exact="pneumonia" post="can occur. Severe cases can be life-threatening or fatal."/>
  <result pre="the Hajj may be at particularly high risk [38]. Seasonal" exact="influenza" post="vaccines are available, and many national guidelines advise annual"/>
  <result pre="significantly immunosuppressed travelers will therefore already have been vaccinated; however," exact="influenza" post="risk should still be discussed as part of the"/>
  <result pre="be discussed as part of the pretravel consultation. The live" exact="influenza" post="vaccination should be avoided in significantly immunosuppressed patients. Inactivated"/>
  <result pre="influenza vaccination should be avoided in significantly immunosuppressed patients. Inactivated" exact="influenza" post="vaccines are safe to administer; however, there may be"/>
  <result pre="there may be an impaired serological response [39]. 6.7 Japanese" exact="encephalitis" post="Japanese encephalitis (JE) is caused by a flavivirus spread"/>
  <result pre="be an impaired serological response [39]. 6.7 Japanese encephalitis Japanese" exact="encephalitis" post="(JE) is caused by a flavivirus spread by Culex"/>
  <result pre="common among survivors. Despite being the leading cause of childhood" exact="encephalitis" post="in Asia [40] it is uncommon among travelers, although"/>
  <result pre="infections range from a mild illness presenting with fever and" exact="diarrhea" post="to paralysis, which occurs in less than 1% of"/>
  <result pre="infectious diseases. Examples of infectious diseases spread by mosquitos include" exact="malaria" post="as well as arboviruses such as dengue, Zika, and"/>
  <result pre="malaria as well as arboviruses such as dengue, Zika, and" exact="yellow fever." post="Sandflies are responsible for spreading diseases such as leishmaniasis"/>
  <result pre="yellow fever. Sandflies are responsible for spreading diseases such as" exact="leishmaniasis" post="and insects of the triatominae subfamily are vectors for"/>
  <result pre="recommended as the first-line repellant for travelers to areas where" exact="malaria" post="and other arthropod-borne infections are endemic. Concentrations of 20%–50%"/>
  <result pre="for a number of infectious diseases including Lyme sisease, babesiosis," exact="tick-borne encephalitis," post="and rickettsial infections. The disease risk depends on the"/>
  <result pre="be divided clinically into uncomplicated and severe disease; most severe" exact="malaria" post="is caused by P. falciparum. An estimated 219 million"/>
  <result pre="caused by P. falciparum. An estimated 219 million cases of" exact="malaria" post="occurred worldwide in 2017, with 92% of these occurring"/>
  <result pre="Malaria life cycle and primary areas of drug activity. The" exact="malaria" post="parasite life cycle involves two hosts. During a blood"/>
  <result pre="a blood-stage infection or at the erythrocytic stage of the" exact="malaria" post="life cycle. Effective chemoprophylaxis exists for malaria and should"/>
  <result pre="stage of the malaria life cycle. Effective chemoprophylaxis exists for" exact="malaria" post="and should be offered to travelers to endemic areas."/>
  <result pre="disease. A British study showed that the majority of imported" exact="malaria" post="cases in the United Kingdom were seen in people"/>
  <result pre="the elderly, tourists, and those presenting to areas where few" exact="malaria" post="cases were seen [50]. Evidence suggests that HIV coinfection"/>
  <result pre="[50]. Evidence suggests that HIV coinfection increases the severity of" exact="malaria" post="[51]. There is no specific data on malaria infection"/>
  <result pre="severity of malaria [51]. There is no specific data on" exact="malaria" post="infection in patients on biological therapies, JAK inhibitors, or"/>
  <result pre="traveler should be advised on mosquito bite avoidance and prescribed" exact="malaria" post="prophylaxis appropriate for their itinerary and destination. Care should"/>
  <result pre="or a severe meningoencephalitis. Cardiac involvement or worsening of previous" exact="cardiomyopathy" post="may also occur [55]. Data on CD in rheumatology"/>
  <result pre="(Latin America) types. Infectious manifestations range from asymptomatic infection to" exact="cutaneous leishmaniasis" post="(CL), mucocutaneous disease, and visceral leishmaniasis (VL). VL or"/>
  <result pre="America) types. Infectious manifestations range from asymptomatic infection to cutaneous" exact="leishmaniasis" post="(CL), mucocutaneous disease, and visceral leishmaniasis (VL). VL or"/>
  <result pre="from asymptomatic infection to cutaneous leishmaniasis (CL), mucocutaneous disease, and" exact="visceral leishmaniasis" post="(VL). VL or kala-azar has a high fatality rate"/>
  <result pre="asymptomatic infection to cutaneous leishmaniasis (CL), mucocutaneous disease, and visceral" exact="leishmaniasis" post="(VL). VL or kala-azar has a high fatality rate"/>
  <result pre="endemic area and a compatible clinical presentation. Most cases of" exact="leishmaniasis" post="in travelers are of the cutaneous form, but cases"/>
  <result pre="condition [62]. Europe has also seen an increasing number of" exact="leishmaniasis" post="cases in patients treated with TNF inhibitors. One study"/>
  <result pre="inhibitors. One study estimated an eightfold higher risk of opportunistic" exact="leishmaniasis" post="in patients treated with monoclonal antibodies compared to controls"/>
  <result pre="may also have longer-term consequences in the form of postinfectious" exact="irritable bowel syndrome" post="[65]. TD is spread via the fecal–oral route due"/>
  <result pre="campylobacter, giardia, listeria, and cryptosporidium [13]. Specifically invasive salmonellosis and" exact="listeriosis" post="are more common in people on TNF inhibitors; this"/>
  <result pre="countries. 8.2 Hepatitis E Hepatitis E infection is caused by" exact="hepatitis" post="E virus (HEV), and there are estimated to be"/>
  <result pre="humans. In low-income countries with poor sanitation, large outbreaks of" exact="hepatitis" post="E occur, most commonly due to genotype 1, and"/>
  <result pre="In high-income countries with safe drinking water sporadic cases of" exact="hepatitis" post="E occur, mostly due to genotype 3. These are"/>
  <result pre="[71]. HEV can also cause chronic infection leading to chronic" exact="hepatitis" post="in immunosuppressed patients. This is typically due to genotype"/>
  <result pre="[73]. Chronic infection in immunosuppressed patients may rapidly progress to" exact="cirrhosis" post="[74] and treatment consists of reducing immunosuppression where possible"/>
  <result pre="syndrome. This can occur when patients with previously unrecognized chronic" exact="strongyloidiasis" post="become immunosuppressed or when an already immunosuppressed patient develops"/>
  <result pre="autoinfection and typically presents as intestinal or pulmonary failure. Disseminated" exact="strongyloidiasis" post="may occur with parasitic spread to any organ including"/>
  <result pre="opinion favors screening patients from endemic areas or with unexplained" exact="eosinophilia" post="before starting treatment with biological therapies [58]. Diagnosis can"/>
  <result pre="lavage. Eosinophilia may be absent [82]. First-line treatment of chronic" exact="strongyloidiasis" post="in developed countries is with ivermectin. Treatment of hyperinfection"/>
  <result pre="possible, and supportive care including organ support and antibiotics. An" exact="infectious disease" post="specialist should always be consulted in the management of"/>
  <result pre="activities that have been associated with these diseases. They include" exact="histoplasmosis" post="and coccidioidomycosis caused by the dimorphic fungi Histoplasma capsulatum"/>
  <result pre="have been associated with these diseases. They include histoplasmosis and" exact="coccidioidomycosis" post="caused by the dimorphic fungi Histoplasma capsulatum and Coccidioides,"/>
  <result pre="patients are asymptomatic. Some cases may result in acute pulmonary" exact="histoplasmosis" post="characterized by fever, cough, chest pain, and fatigue. Most"/>
  <result pre="Africa, and Australia [87]. Treatment of short-lived, mild to moderate" exact="histoplasmosis" post="is not usually required in immunocompetent patients. Treatment of"/>
  <result pre="is not usually required in immunocompetent patients. Treatment of chronic" exact="histoplasmosis" post="is with systemic antifungals, e.g., itraconazole. Severe or disseminated"/>
  <result pre="Case series suggest that between 17% and 29% of community-acquired" exact="pneumonia" post="cases in endemic areas are due to coccidioidomycosis [90,91]."/>
  <result pre="of community-acquired pneumonia cases in endemic areas are due to" exact="coccidioidomycosis" post="[90,91]. The disease can be asymptomatic or subclinical or"/>
  <result pre="approximately 160 deaths per year, and autoimmune conditions such as" exact="rheumatoid arthritis," post="systemic lupus erythematosus, and vasculitis are more common on"/>
  <result pre="deaths per year, and autoimmune conditions such as rheumatoid arthritis," exact="systemic lupus erythematosus," post="and vasculitis are more common on death certificates associated"/>
  <result pre="per year, and autoimmune conditions such as rheumatoid arthritis, systemic" exact="lupus erythematosus," post="and vasculitis are more common on death certificates associated"/>
  <result pre="autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, and" exact="vasculitis" post="are more common on death certificates associated with coccidioidomycosis"/>
  <result pre="and vasculitis are more common on death certificates associated with" exact="coccidioidomycosis" post="than on those of matched controls [93]. One case"/>
  <result pre="controls [93]. One case series showed that patients with inflammatory" exact="arthritis" post="treated with infliximab are at greater risk of developing"/>
  <result pre="treated with infliximab are at greater risk of developing symptomatic" exact="coccidioidomycosis" post="than those not treated with infliximab [94]. Most infections"/>
  <result pre="fluconazole [92]. Immunosuppressed patients are at greater risk of severe" exact="pneumonia" post="and disseminated disease. The commonest sites of dissemination are"/>
  <result pre="of dissemination are skin, bone, and meninges. Patients diagnosed with" exact="coccidioidomycosis" post="while being treated with biological therapies should be started"/>
  <result pre="reduce the transmission of blood-borne viruses (BBVs) such as HIV," exact="hepatitis" post="B and C, and other sexually transmitted infections (STIs)."/>
  <result pre="the rise of multidrug-resistant STIs such as extensively drug resistant" exact="gonorrhea" post="which have very limited treatment options [97] as such"/>
  <result pre="Human migration and travel have played a pivotal role in" exact="infectious disease" post="emergence for centuries. For example, the arrival of smallpox"/>
  <result pre="infectious disease emergence for centuries. For example, the arrival of" exact="smallpox" post="in the New World with European colonization led to"/>
  <result pre="(VTE) is used to describe deep vein thrombosis (DVT) and" exact="pulmonary embolism" post="(PE). A blood clot forms in a deep vein"/>
  <result pre="wide variety of disorders such as inflammatory bowel disease and" exact="rheumatoid arthritis" post="has been suggested as a contributing factor in the"/>
  <result pre="variety of disorders such as inflammatory bowel disease and rheumatoid" exact="arthritis" post="has been suggested as a contributing factor in the"/>
  <result pre="immunosuppressive treatments have the potential to increase the incidence of" exact="skin cancer" post="[113]. 10 Conclusions In summary the travel-related infection risks"/>
  <result pre="treatments have the potential to increase the incidence of skin" exact="cancer" post="[113]. 10 Conclusions In summary the travel-related infection risks"/>
  <result pre="considerations for North American immigrants visiting friends and relativesJAMA2912320042856286415199037 5FennerL.WeberR.SteffenR.SchlagenhaufP.Imported" exact="infectious disease" post="and purpose of travel, SwitzerlandEmerg Infect Dis132200721722217479882 6KooS.MartyF.M.BadenL.R.Infectious complications"/>
  <result pre="of serious infection, including site-specific and bacterial intracellular infection, in" exact="rheumatoid arthritis" post="patients receiving anti-tumor necrosis factor therapy: results from the"/>
  <result pre="serious infection, including site-specific and bacterial intracellular infection, in rheumatoid" exact="arthritis" post="patients receiving anti-tumor necrosis factor therapy: results from the"/>
  <result pre="therapy: mechanisms of action and clinical considerationsAnn Intern Med8431976304315769625 11McLean-TookeA.AldridgeC.WaughS.SpickettG.P.KayL.Methotrexate," exact="rheumatoid arthritis" post="and infection risk: what is the evidence?Rheumatology488200986787119447771 12Public Health"/>
  <result pre="mechanisms of action and clinical considerationsAnn Intern Med8431976304315769625 11McLean-TookeA.AldridgeC.WaughS.SpickettG.P.KayL.Methotrexate, rheumatoid" exact="arthritis" post="and infection risk: what is the evidence?Rheumatology488200986787119447771 12Public Health"/>
  <result pre="CentreYellow fever2019Available from:https://travelhealthpro.org.uk/factsheet/18/yellow-fever 19Public Health EnglandThe green book: chapter 35," exact="yellow fever" post="England2013 20CDC Yellow Fever: Medical Waivers (Exemptions). Available from:"/>
  <result pre="20CDC Yellow Fever: Medical Waivers (Exemptions). Available from: https://www.cdc.gov/travel-training/local/PreTravelConsultationandBestPractices/page24195.html. 21NaTHNaC" exact="yellow fever" post="zone: medical letter of exemption2015Available from:https://nathnacyfzone.org.uk/factsheet/6/medical-letter-of-exemption 22Public Health EnglandThe"/>
  <result pre="recommendationsJ Travel Med2512018 26Public Health EnglandThe green book: chapter 17," exact="hepatitis" post="A2013 27WongP.K.K.BaggaH.BarrettC.HanrahanP.JohnsonD.KatribA.A practical approach to vaccination of patients with"/>
  <result pre="Health EnglandThe green book: chapter 27, rabiesEngland2018 29FooksA.R.BanyardA.C.HortonD.L.JohnsonN.McElhinneyL.M.JacksonA.C.Current status of" exact="rabies" post="and prospects for eliminationLancet384995120141389139924828901 30National travel health Network and"/>
  <result pre="pre-travel counseling: status quo 2014Trav Med Infect Dis1232014219228 36Marc LaForceF.RavenscroftN.DjingareyM.VivianiS.Epidemic" exact="meningitis" post="due to Group A Neisseria meningitidis in the African"/>
  <result pre="meningitis due to Group A Neisseria meningitidis in the African" exact="meningitis" post="belt: a persistent problem with an imminent solutionVaccine27Suppl. 22009B13B1919477559"/>
  <result pre="England. 41LindquistL.Recent and historical trends in the epidemiology of Japanese" exact="encephalitis" post="and its implication for risk assessment in travellersJ Travel"/>
  <result pre="arthropod bite avoidanceJ Travel Med173201018219220536888 49World Health OrganizationThis year's World" exact="malaria" post="report at a glance2018Available from:https://www.who.int/malaria/media/world-malaria-report-2018/en/ 50CheckleyA.M.SmithA.SmithV.BlazeM.BradleyD.ChiodiniP.L.Risk factors for mortality"/>
  <result pre="a glance2018Available from:https://www.who.int/malaria/media/world-malaria-report-2018/en/ 50CheckleyA.M.SmithA.SmithV.BlazeM.BradleyD.ChiodiniP.L.Risk factors for mortality from imported falciparum" exact="malaria" post="in the United Kingdom over 20 years: an observational"/>
  <result pre="disease; experience from a non-endemic countryClin Microbiol Infect219201585486026055418 58BartalesiF.ScireC.Requena-MendezA.AbadM.A.BuonfrateD.CaporaliR.Recommendations for" exact="infectious disease" post="screening in migrants to Western Europe with inflammatory arthropathies"/>
  <result pre="individualsClin Microbiol Infect204201428629924450618 63ZangerP.KotterI.KremsnerP.G.GabryschS.Tumor necrosis factor alpha antagonist drugs and" exact="leishmaniasis" post="in EuropeClin Microbiol Infect187201267067621985586 64BarrettJ.BrownM.Travellers' diarrhoeaBMJ3532016i193727094342 65SteffenR.Epidemiology of travellers'"/>
  <result pre="travellers: an updateTrav Med Infect Dis2120182835 70ReinD.B.StevensG.A.TheakerJ.WittenbornJ.S.WiersmaS.T.The global burden of" exact="hepatitis" post="E virus genotypes 1 and 2 in 2005Hepatology554201298899722121109 71AggarwalR.The"/>
  <result pre="genotypes 1 and 2 in 2005Hepatology554201298899722121109 71AggarwalR.The global prevalence of" exact="hepatitis" post="E virus infection and susceptibility: a systematic review2010Immunization, Vaccines"/>
  <result pre="and Biologicals World Health Organization 72KamarN.SelvesJ.MansuyJ.M.OuezzaniL.PeronJ.M.GuitardJ.Hepatitis E virus and chronic" exact="hepatitis" post="in organ-transplant recipientsN Engl J Med3588200881181718287603 73FraticelliP.BagnarelliP.TarantinoG.MartinoG.P.BenfaremoD.NobiliL.Chronic hepatitis E"/>
  <result pre="and chronic hepatitis in organ-transplant recipientsN Engl J Med3588200881181718287603 73FraticelliP.BagnarelliP.TarantinoG.MartinoG.P.BenfaremoD.NobiliL.Chronic" exact="hepatitis" post="E in a patient treated with rituximab and mycophenolate"/>
  <result pre="rituximab and mycophenolate mofetil for Sjogren's syndromeRheumatology551220162275227727498353 74HaagsmaE.B.van den BergA.P.PorteR.J.BenneC.A.VennemaH.ReimerinkJ.H.Chronic" exact="hepatitis" post="E virus infection in liver transplant recipientsLiver Transpl144200854755318383084 75KamarN.IzopetJ.TriponS.BismuthM.HillaireS.DumortierJ.Ribavirin"/>
  <result pre="virus infection in liver transplant recipientsLiver Transpl144200854755318383084 75KamarN.IzopetJ.TriponS.BismuthM.HillaireS.DumortierJ.Ribavirin for chronic" exact="hepatitis" post="E virus infection in transplant recipientsN Engl J Med3701220141111112024645943"/>
  <result pre="79JourdanP.M.LambertonP.H.L.FenwickA.AddissD.G.Soil-transmitted helminth infectionsLancet39110117201825226528882382 80KrishnamurthyR.DincerH.E.WhittemoreD.Strongyloides stercoralis hyperinfection in a patient with" exact="rheumatoid arthritis" post="after anti-TNF-alpha therapyJ Clin Rheumatol133200715015217551383 81KhaliqM.F.IhleR.E.PerryJ.Immunosuppression with antitumour necrosis"/>
  <result pre="helminth infectionsLancet39110117201825226528882382 80KrishnamurthyR.DincerH.E.WhittemoreD.Strongyloides stercoralis hyperinfection in a patient with rheumatoid" exact="arthritis" post="after anti-TNF-alpha therapyJ Clin Rheumatol133200715015217551383 81KhaliqM.F.IhleR.E.PerryJ.Immunosuppression with antitumour necrosis"/>
  <result pre="Society of AmericaClin Infect Dis457200780782517806045 89HageC.A.BowyerS.TarvinS.E.HelperD.KleimanM.B.WheatL.J.Recognition, diagnosis, and treatment of" exact="histoplasmosis" post="complicating tumor necrosis factor blocker therapyClin Infect Dis5012010859219951231 90KimM.M.BlairJ.E.CareyE.J.WuQ.SmilackJ.D.Coccidioidal"/>
  <result pre="93HuangJ.Y.BristowB.ShafirS.SorvilloF.Coccidioidomycosis-associated deaths, United States, 1990–2008Emerg Infect Dis181120121723172823092645 94BergstromL.YocumD.E.AmpelN.M.VillanuevaI.LisseJ.GluckO.Increased risk of" exact="coccidioidomycosis" post="in patients treated with tumor necrosis factor alpha antagonistsArthritis"/>
  <result pre="Haemost113620151176118325472800 112National Travel Health Network and CentreSun protection2018Available from:https://travelhealthpro.org.uk/factsheet/23/sun-protection 113GerliniG.RomagnoliP.PimpinelliN.Skin" exact="cancer" post="and immunosuppressionCrit Rev Oncol Hematol561200512713615978830"/>
 </snippets>
</snippetsTree>
